2019

Juan Oliva-Moreno, Jaume Puig-Junoy, Marta Trapero-Bertran, David Epstein, Carme Pinyol, José Antonio Sacristán, ‘Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?’, Value in Health, (2019).

Carlos Campillo-Artero, Jaume Puig-Junoy, Anthony J. Culyer, ‘Authors’ Reply to Angelis and Kanavos: “Does MCDA Trump CEA?”‘, Applied Health Economics and Health Policy, (2019); 17, 125.

Jaume Puig-Junoy, Carlos Campillo-Artero, ‘Pricing Orphan Drugs‘, The Lancet, (2019), 393.

Jaume Puig-Junoy, Carlos Campillo-Artero, ‘Innovación y competencia en el secotr farmacéutco en la época de la medicina de precisión’, Papeles de Economía Española, (2019); 160, 52-63.

Carlos Campillo‑Artero, Jaume Puig‑Junoy, José Luis Segú‑Tolsa, Marta Trapero‑Bertran, ‘Price Models for Multi‑indication Drugs: A Systematic Review‘, Applied Health Economics and Health Policy, (2019).

A. Barberan-Garcia, M. Ubre, N. Pascual-Argente, R. Risco, J. Faner, J. Balust, A. M. Lacy, J. Puig-Junoy, J. Roca and G. Martinez-Palli, ‘Post-discharge impact and cost-consequence analysis of prehabilitation in high-risk patients undergoing major abdominal surgery: secondary results from a randomised controlled trial‘, British Journal of Anaesthesia, (2019); 123 (4), 450-456.